La chaîne d'options affiche les données clés des options sur actions de I-MAB à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour I-MAB..

I-MAB (NASDAQ:IMAB) Stock, Chaîne d'Options

I-MAB-SPONSORED ADR

I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

Health Care

Press Releases

I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers

Earnings

I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update

News

I-Mab to Participate in September Investor Conferences

Management

I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

Everest Medicines Announces 2025 Interim Results: 'Dual-Engine'  Strategy Driving Strong Synergies Between Commercialization and R&D

I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments

Small Cap

Opinion

Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms

I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

ENGN

GDTC

GTBP

IMAB

IOVA

NBTX

ONCO

PSTV

Absci

Akebia Therapeutics

Astria Therapeutics

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

CareDx

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Erasca

Geron

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gyre Therapeutics

Inventiva S.A. - American Depository Shares

Inventiva

Kodiak Sciences

MeiraGTx Hldgs

Myriad Genetics

Nurix Therapeutics

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Regenxbio

Savara

Tyra Biosciences

UroGen Pharma

Vir Biotechnology

BTIG

Leerink Partners

Needham

HC Wainwright & Co.

Comments

I-MAB

I-MAB (IMAB) Options

I-MAB (NASDAQ:IMAB) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL